Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)

3. juli 2026 oppdatert av: CSL Behring

A Phase 1b, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease Undergoing Dialysis

This is a phase 1b, partial-blind (Sponsor unblinded), randomized, multicenter, placebo-controlled study. The primary objective of this study is to evaluate the pharmacokinetics (PK) of CSL300 after single and multiple doses in Chinese participants with end stage kidney disease (ESKD) undergoing dialysis.

Studieoversikt

Status

Rekruttering

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

24

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Beijing, Kina, 100044
        • Rekruttering
        • Peking University People's Hospital

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  • Participants has provided written informed consent and is willing and able to adhere to all protocol requirements.
  • Aged 18 or older, inclusive, at the time of providing written informed consent.
  • Diagnosis of ESKD undergoing maintenance dialysis for at least 12 weeks before Screening.

Exclusion Criteria:

  • Exclusion related to risk of infection: concomitant use of systemic immunosuppressant agents, primary immunodeficiency, positive test for active tuberculosis (TB), history of latent TB without completion of full course of prophylactic treatment, evidence of human immunodeficiency virus infection during Screening, seropositivity for hepatitis B surface antigen or positive hepatitis B virus (HBV) DNA during Screening, seropositivity for hepatitis C virus ribonucleic acid during Screening, diagnosis of clinically significant active infection, history of / OR current invasive fungal infection OR other opportunistic infection OR recurrent cellulitis (defined as 2 or more episodes in the year prior to screening), administration of a live vaccine within 6 weeks of start of Screening, presence of urinary catheter, or evidence of wet gangrene or nonhealing ulcers.
  • Exclusion related to laboratory abnormalities: abnormal liver function tests, neutropenia, thrombocytopenia, or significant anemia.
  • Exclusion related to medical history: any life-threatening disease expected to result in death within 12 months (other than cardiovascular disease), evidence of active hepatic disease and / or moderate or severe hepatic impairment, recent unplanned hospitalization (< 30 days) prior to Screening, recent (< 3 months) major surgery or planned major surgery known at the time of Screening, poorly controlled hypertension, a present or previous (< 5 years) malignancy except for basal cell carcinoma, fully excised squamous cell carcinoma of the skin, or nonrecurrent (< 5 years of Screening) cervical carcinoma in situ, active or recent (< 30 days of Screening) clinically severe bleeding, a scheduled kidney transplant within 6 months of Screening, a history of anaphylaxis or hypersensitivity to CSL300 or any constituents of the product, or a history of demyelinating disorders.
  • Exclusion related to risk of gastrointestinal perforation: a history of GI perforation, inflammatory bowel disease (except fully excised ulcerative colitis), or peptic ulcer disease (< 12 months before Screening), a history of diverticular disease or diverticulitis (except if disease has been fully excised). An incidental finding of diverticulosis (presence of small diverticula) and no history of symptoms, complications, or any episodes requiring treatment may be eligible for the study based on investigator's judgment. However, any history of complications, inflammation, or infection suggestive of diverticulitis or diverticular disease is exclusionary, inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis except if fully excised, or prior gastric bypass surgery.
  • Exclusion related to treatment compliance: evidence of inadequate dialysis, unwillingness or inability to comply with study procedures, a history of noncompliance with medical treatments, or ongoing alcohol or illicit substance abuse.
  • Current or recent participation in research study involving an experimental agent < 3 months of Screening.
  • Pregnant, breastfeeding, or unwillingness to practice adequate contraception during the study and for 5 months after the last dose of investigational product.
  • The presence of any condition that in the opinion of the Investigator would (1) compromise the safety of the participant in case of participation in the study, (2) compromise the quality of the data, and / or (3) limit the life expectancy of the participant to < 1 year.
  • The Sponsor determines that the participant is no longer needed for participation in study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: CSL300 (Clazakizumab)
Participants will receive CSL300 once every 4 weeks (Q4W) as a slow intravenous (IV) bolus, for a total of 20 weeks during the Treatment Period.
CSL300 is a humanized anti-interleukin 6 (anti-IL-6) monoclonal antibody (mAb).
Placebo komparator: Placebo
Participants will receive a placebo matching to CSL300 Q4W as a slow IV bolus, for a total of 20 weeks during the treatment period.
Placebo is a solution for injection matching the excipient content and concentration of the CSL300 product, minus the active ingredient.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
Area Under the Concentration-time (AUC) Curve of CSL300 Over 1 Dosing Interval After Multiple Doses (AUC0-tau,MD)
Tidsramme: Day 85 up to Day 113
Day 85 up to Day 113
Trough Concentration at Steady State (Ctrough,ss)
Tidsramme: Up to Day 141
Up to Day 141

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Event of Special Interests (AESIs)
Tidsramme: Up to Day 225 (End of Study [EoS])
The following adverse events (AEs) are defined as AESIs: relevant infections (tuberculosis, herpes simplex virus, herpes zoster, human papillomavirus, human immunodeficiency virus, hepatitis B, hepatitis C, and invasive fungal infections), and demyelinating disorders.
Up to Day 225 (End of Study [EoS])
Percentage of Participants With TEAEs, SAEs, and AESIs
Tidsramme: Up to Day 225 (EoS)
The following AEs are defined as AESIs: relevant infections (tuberculosis, herpes simplex virus, herpes zoster, human papillomavirus, human immunodeficiency virus, hepatitis B, hepatitis C, and invasive fungal infections), and demyelinating disorders.
Up to Day 225 (EoS)
Percentage of Participants With a Clinically Significant Change From Baseline in Laboratory Test Results
Tidsramme: At Baseline and up to Day 225 (EoS)
Laboratory assessments will include hematology parameters such as white blood cells (leukocytes), neutrophils, and platelets; chemistry evaluations including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin; a lipid panel comprising total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides; and immunogenicity testing.
At Baseline and up to Day 225 (EoS)
Number of Participants With Antidrug Antibodies
Tidsramme: At Days 1, 29, 85, and 169
The detection of antibodies to CSL300 will be performed using a validated immunoassay method.
At Days 1, 29, 85, and 169
Maximum Observed Concentration (Cmax) of CSL300
Tidsramme: Up to Day 169
Up to Day 169
Area Under the Concentration-Time Curve From Time 0 to Day 28 (AUC0-28d) of CSL300
Tidsramme: Up to Day 28
Up to Day 28
Trough Concentration (Ctrough) of CSL300
Tidsramme: Up to Day 141
Up to Day 141
Time to Reach Cmax (Tmax) of CSL300
Tidsramme: Up to Day 85
Up to Day 85
Change From Baseline on log-scale High-Sensitivity C-reactive Protein (hs-CRP)
Tidsramme: At Baseline, Week 12, and Week 24
At Baseline, Week 12, and Week 24
Plasma Interleukin-6 (IL-6) Free and Total Levels
Tidsramme: At Weeks 12 and 24
At Weeks 12 and 24

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. juni 2026

Primær fullføring (Antatt)

30. august 2027

Studiet fullført (Antatt)

30. november 2027

Datoer for studieregistrering

Først innsendt

26. mai 2026

Først innsendt som oppfylte QC-kriteriene

26. mai 2026

Først lagt ut (Faktiske)

2. juni 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

7. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

IPD-delingstidsramme

Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.

Tilgangskriterier for IPD-deling

Proposed research should seek to answer a previously unanswered important medical or scientific question.

Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.

If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere